332 470

Cited 0 times in

병리학적 T0 병기 전립선암의 병리학적 특성과 예후

DC Field Value Language
dc.contributor.author김원태-
dc.contributor.author이승렬-
dc.contributor.author최영득-
dc.contributor.author함원식-
dc.date.accessioned2015-04-24T16:32:53Z-
dc.date.available2015-04-24T16:32:53Z-
dc.date.issued2009-
dc.identifier.issn2005-6737-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/103719-
dc.description.abstractPURPOSE: We evaluated the pathologic characteristics and prognosis of pathologic T0 (pT0) prostate cancer (PC). MATERIALS AND METHODS: Of 1,196 consecutive men who underwent radical prostatectomy (RP) between January 1992 and November 2008, 34 patients (mean age, 68.8+/-7.9 years; range, 48-85) had pT0 PC. They were categorized into 4 groups according to neoadjuvant hormone therapy (NHT) and diagnostic methods. The initial PSA, 5 alpha-reductase inhibitor (5alphaRI), Gleason score of prostatic needle biopsy (PNB) or transurethral resection of the prostate (TURP), clinical stage, and presence of high-grade prostatic intraepithelial neoplasia were evaluated. Clinical and biochemical progression were also evaluated. RESULTS: 34 patients were categorized into 4 groups (Group I: 9 without NHT, diagnosed by PNB [1.1%]; Group II: 8 without NHT, diagnosed by TURP [11.3%]; Group III: 16 with NHT, diagnosed by PNB [5.5%]; Group IV: 1 with NHT, diagnosed by TURP [3.8%]). Group I had serum prostate-specific antigen (PSA)<15.0 ng/ml, one positive biopsy core, and a Gleason score< or =7. Group II had serum PSA<10.1 ng/ml, chips involved with cancer<10.0%, and a Gleason score< or =6. There were more patients taking 5alphaRI and high-grade PIN among patients without NHT. None of patients with pathologic pT0 PC had clinical or biochemical progression during follow-up, except 3 patients with NHT (mean, 22 months; range, 2-105 months). CONCLUSIONS: Patients without NHT had more favorable clinical and pathologic results. In our study, except for 3 patients with NHT, all patients had undetectable PSA levels after RP. We need more time for follow-up to conclude whether the prognosis of pT0 PC is favorable.-
dc.description.statementOfResponsibilityopen-
dc.format.extent229~236-
dc.relation.isPartOfKOREAN JOURNAL OF UROLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.title병리학적 T0 병기 전립선암의 병리학적 특성과 예후-
dc.title.alternativePathologic Characteristics and Prognosis of Pathologic T0 Prostate Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Urology (비뇨기과학)-
dc.contributor.googleauthor이승렬-
dc.contributor.googleauthor함원식-
dc.contributor.googleauthor김원태-
dc.contributor.googleauthor주희정-
dc.contributor.googleauthor이진선-
dc.contributor.googleauthor최영득-
dc.identifier.doi10.4111/kju.2009.50.3.229-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00773-
dc.contributor.localIdA02915-
dc.contributor.localIdA04111-
dc.contributor.localIdA04337-
dc.relation.journalcodeJ02134-
dc.identifier.eissn2005-6745-
dc.subject.keywordProstatic neoplasms-
dc.subject.keywordProstatectomy-
dc.contributor.alternativeNameKim, Won Tae-
dc.contributor.alternativeNameLee, Seung Ryeol-
dc.contributor.alternativeNameChoi, Young Deuk-
dc.contributor.alternativeNameHam, Won Sik-
dc.contributor.affiliatedAuthorKim, Won Tae-
dc.contributor.affiliatedAuthorLee, Seung Ryeol-
dc.contributor.affiliatedAuthorChoi, Young Deuk-
dc.contributor.affiliatedAuthorHam, Won Sik-
dc.citation.volume50-
dc.citation.number3-
dc.citation.startPage229-
dc.citation.endPage236-
dc.identifier.bibliographicCitationKOREAN JOURNAL OF UROLOGY, Vol.50(3) : 229-236, 2009-
dc.identifier.rimsid36648-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.